28 April 2023
SHARE NOW
Cell Therapy
Scaling Up
Viral/Non-Viral Vectors
Katja Betts, CEO at PROGEN, discusses the core issues affecting biotechs working with AAV and how these could be addressed at both the individual team and industry-wide levels.
Katja begins by introducing the challenges facing biotechs within AAV, and explores the possibility for devising standards for the field. Katja continues to explore challenges that occur when scaling up AAV operations, before sharing her top tips for developing AAV.
Finally, Katja discusses her AAV ‘headline highlights’ from the past year or so, and suggests what we might be able to expect from the next 5 years.
This interview has been produced in partnership with PROGEN and was recorded at Advanced Therapies Week 2023.
More like this
Intensified extracellular vesicle production in fixed-bed bioreactors: Discover low-footprint, automated solutions for low-cost extracellular vesicles manufacturing
Are you looking for a cost-effective, high-productivity extracellular vesicle (EV) production platform that overcomes traditional manufacturing challenges? Join us to discover how Univercells Technologies’ scalable fixed-bed design is transforming EV manufacturing.
14 May 2024
Women in Advanced Therapies Global 2024, Virtual Event
Experience Women in Advanced Therapies Global, a 24-hour online event uniting the community in celebration of inspiration, innovation, and empowerment. Access exclusive insights, workshops, and networking opportunities from anywhere.
8 April 2024
